GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Canopy Growth Corp (NAS:CGC) » Definitions » Debt-to-EBITDA

Canopy Growth (Canopy Growth) Debt-to-EBITDA : -0.89 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Canopy Growth Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Canopy Growth's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $78.5 Mil. Canopy Growth's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $438.2 Mil. Canopy Growth's annualized EBITDA for the quarter that ended in Dec. 2023 was $-579.9 Mil. Canopy Growth's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.89.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Canopy Growth's Debt-to-EBITDA or its related term are showing as below:

CGC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -15.89   Med: -0.46   Max: 4.29
Current: -0.66

During the past 13 years, the highest Debt-to-EBITDA Ratio of Canopy Growth was 4.29. The lowest was -15.89. And the median was -0.46.

CGC's Debt-to-EBITDA is ranked worse than
100% of 660 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs CGC: -0.66

Canopy Growth Debt-to-EBITDA Historical Data

The historical data trend for Canopy Growth's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Canopy Growth Debt-to-EBITDA Chart

Canopy Growth Annual Data
Trend Jul13 Dec14 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.47 -0.45 -1.11 -13.54 -0.46

Canopy Growth Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.89 -0.46 25.99 -1.98 -0.89

Competitive Comparison of Canopy Growth's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Canopy Growth's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Canopy Growth's Debt-to-EBITDA falls into.



Canopy Growth Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Canopy Growth's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(427.957 + 607.042) / -2268.247
=-0.46

Canopy Growth's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(78.53 + 438.219) / -579.876
=-0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Canopy Growth  (NAS:CGC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Canopy Growth Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Canopy Growth's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Canopy Growth (Canopy Growth) Business Description

Traded in Other Exchanges
Address
1 Hershey Drive, Smiths Falls, ON, CAN, K7A 0A8
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include sports drink BioSteel, skincare products under This Works, Martha Stewart CBD, and Storz & Bickel vaporizers. Canopy growth is attempting to merge its U.S. assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.
Executives
Theresa Yanofsky director 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
David Angelo Lazzarato director 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
Judy Schmeling director C/O HSN, INC., 1 HSN DRIVE, ST.PETERSBURG FL 33729
Hong Judy Eun Joo officer: See Remarks 1 HERSHEY DRIVE, SMITHS FALLS Z4 K7A 0A8
David Eric Klein director, officer: Chief Executive Officer 207 HIGH POINT DRIVE, VICTOR NY 14564
Thomas Carlton Stewart officer: See Remarks 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
Christelle Gedeon officer: See Remarks 3 HOLLYHOCK COURT, TORONTO Z4 M3B 0B4
Garth Hankinson director C/O CONSTELLATION BRANDS, INC., 207 HIGH POINT DRIVE, BLDG. 100, VICTOR NY 14564
Greenstar Ii Holdings Llc 10 percent owner 207 HIGH POINT DRIVE, BUILDING 100, VICTOR NY 14564
Greenstar Ii Llc 10 percent owner 207 HIGH POINT DRIVE, BUILDING 100, VICTOR NY 14564
Rade Nikola Kovacevic officer: President 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
Phillip Stephen Shaer officer: Chief Legal Officer 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
Grant Julious C. Jr officer: Chief Commercial Officer 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
Sabia James A. Jr. director C/O CONSTELLATION BRANDS, INC., 207 HIGH POINT DRIVE, BLDG. 100, VICTOR NY 14564
Tomas Iv Shipley officer: See Remarks 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8